Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:36:11.411Z.
Calculation as of: 2026-10-06T15:36:11.411Z.
Quote observation: 2026-10-06T15:35:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ea268c636d02c1563f9a0cc17fa45ef3048b6802d4031696aa30e1bc9d7aaf2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Connect Biopharma Holdings Limited
Market Cap
$60.32M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$60.24M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Connect Biopharma Holdings Limited (CNTB) | $60.32M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.17M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $60.24M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $61.23M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $59.10M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.34M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.87M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $63.14M | N/A | 7.83x | 18.88x | 17.80x |
| Kalaris Therapeutics Inc (KLRS)vs › | $63.26M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
